BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23349440)

  • 1. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.
    Lewis RE; Albert NP; Liao G; Wang W; Prince RA; Kontoyiannis DP
    J Antimicrob Chemother; 2013 May; 68(5):1148-51. PubMed ID: 23349440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
    Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
    J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
    Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
    J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
    Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
    Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis.
    Mihara T; Kakeya H; Izumikawa K; Obata Y; Nishino T; Takazono T; Kosai K; Morinaga Y; Kurihara S; Nakamura S; Imamura Y; Miyazaki T; Tsukamoto M; Yamamoto Y; Yanagihara K; Tashiro T; Kohno S
    J Infect Chemother; 2014 Feb; 20(2):104-8. PubMed ID: 24462443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
    Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
    Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.
    Martín MT; Gavaldà J; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Jordano Q; Ruiz I; Rosal M; Almirante B; Pahissa A
    J Antimicrob Chemother; 2003 Dec; 52(6):1032-4. PubMed ID: 14613950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
    Warn PA; Sharp A; Morrissey G; Denning DW
    Int J Antimicrob Agents; 2010 Feb; 35(2):146-51. PubMed ID: 20015618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galleria mellonella as a host model to study Aspergillus terreus virulence and amphotericin B resistance.
    Maurer E; Browne N; Surlis C; Jukic E; Moser P; Kavanagh K; Lass-Flörl C; Binder U
    Virulence; 2015; 6(6):591-8. PubMed ID: 26107350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
    Lewis RE; Albert ND; Liao G; Hou J; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.
    Alsaadi M; Italia JL; Mullen AB; Ravi Kumar MN; Candlish AA; Williams RA; Shaw CD; Al Gawhari F; Coombs GH; Wiese M; Thomson AH; Puig-Sellart M; Wallace J; Sharp A; Wheeler L; Warn P; Carter KC
    J Control Release; 2012 Jun; 160(3):685-91. PubMed ID: 22516093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
    Andes D; Safdar N; Marchillo K; Conklin R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
    J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.
    Kirkpatrick WR; Najvar LK; Vallor AC; Wiederhold NP; Bocanegra R; Pfeiffer J; Perkins K; Kugler AR; Sweeney TD; Patterson TF
    J Antimicrob Chemother; 2012 Apr; 67(4):970-6. PubMed ID: 22240402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of fungicidal activity against Candida tropicalis on the efficacy of micafungin and liposomal amphotericin B in a neutropenic murine lethal infection model.
    Takemoto K; Nakayama T; Kanazawa K; Ueda Y
    Pharmacology; 2012; 90(3-4):133-45. PubMed ID: 22847175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis.
    Mouton JW; te Dorsthorst DT; Meis JF; Verweij PE
    Med Mycol; 2009 Dec; 47(8):802-7. PubMed ID: 19180360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.